CJC-1295 + Ipamorelin (blend) vs Tesamorelin
This is the choice behind the CJC-1295 + Ipamorelin blend versus the Recomposition Stack (Ipamorelin + Tesamorelin): both pair Ipamorelin with a GHRH analogue. Tesamorelin is the full-length, clinically approved analogue with phase 3 data; CJC-1295 without DAC is a shorter, stabilised research fragment.
CJC-1295 + Ipamorelin (blend)
This is a blend rather than a single compound, and no published study has evaluated this specific two-peptide combination — the evidence below is the literature for each constituent, cited separately.
BEST STUDIED FOR
Combined GHRH- and ghrelin-receptor GH-pulse research
R609View product →
Tesamorelin
Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone (GHRH).
BEST STUDIED FOR
GHRH-analogue and visceral-fat research
R1 199View product →
Side by side · to buy
Price, purity and dispatch
| Compare | CJC-1295 + Ipamorelin (blend)10mg | Tesamorelin10 mg · more sizes |
|---|---|---|
| Price | R609 | fromR1,199 |
| Cost per mg | R60.9 / mgBlend total | R120 / mg |
| Purity (Janoshik) | On request | On request |
| Stock | Restocking | Restocking |
| Dispatch | When restocked | When restocked |
| Certificate | Request CoA | Request CoA |
| Literature | 3 papers → | 3 papers → |
| Research focus | Combined GHRH- and ghrelin-receptor GH-pulse research | GHRH-analogue and visceral-fat research |
| Notify me | Notify me |
Prices are read live from the catalogue. Cost per mg is the vial price over its stated mg. Purity is shown only where the certificate is published. Every compound is supplied for laboratory research only.
RESEARCH PROFILES
0–10 per area, scored from the depth of published research — not a measure of effect.
| Area | CJC-1295 + Ipamorelin (blend) | Tesamorelin |
|---|---|---|
| Fat Loss & Metabolism | 5 | 8 |
| Appetite Control | 3 | 3 |
| Muscle & Body Composition | 9 | 7 |
| Recovery & Repair | 7 | 6 |
| Skin, Hair & Glow | 5 | 5 |
| Gut & Immune | 5 | 4 |
| Cognition & Focus | 4 | 7 |
| Mood & Calm | 4 | 5 |
| Sleep & Recovery Rhythm | 7 | 7 |
| Longevity & Energy | 6 | 7 |
SIDE BY SIDE
| CJC-1295 + Ipamorelin (blend) | Tesamorelin | |
|---|---|---|
| The key difference | Short-acting GHRH(1-29) analogue + ghrelin agonist | Full-length, approved GHRH(1-44) analogue |
| Class | GH secretagogues | GH secretagogues |
| Mechanism | This is a blend rather than a single compound, and no published study has evaluated this specific two-peptide combination — the evidence below is the literature for each constituent, cited separately. | Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone (GHRH). |
| Status | A research blend of two investigational GH secretagogues; neither component is an approved medicine and the blend itself has not been studied. | An approved medicine (US) for excess abdominal fat in HIV-associated lipodystrophy; research use elsewhere. |
| Reported safety signals | No human safety data for the blend; each component has only limited, short-term human exposure. | Label-level trial data exist for its approved indication, including IGF-1 elevation and injection-site effects. |
| A key study | Measured GH responses to GHRH(1-29)-NH2 and a D-Ala2-substituted analogue in normal men across a dose range. (Peptides 1985, PMID 2866496) | A pooled analysis of two phase-3 trials reported that tesamorelin reduced visceral adipose tissue in HIV patients with excess abdominal fat. (J Clin Endocrinol Metab 2010, PMID 20554713) |
WHEN TO RESEARCH WHICH
Tesamorelin brings the clinical dataset; CJC-1295 (no DAC) is the common short-acting research partner, pre-blended here with Ipamorelin. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.
REFERENCES (PUBMED)
- [CJC-1295 + Ipamorelin (blend)] Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men — Peptides 1985. PMID 2866496
- [CJC-1295 + Ipamorelin (blend)] Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies — J Med Chem 1998. PMID 9513600
- [CJC-1295 + Ipamorelin (blend)] Ipamorelin, the first selective growth hormone secretagogue — Eur J Endocrinol 1998. PMID 9849822
- [Tesamorelin] Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials — J Clin Endocrinol Metab 2010. PMID 20554713
- [Tesamorelin] Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial — JAMA 2014. PMID 25038357
- [Tesamorelin] Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension — J Acquir Immune Defic Syndr 2010. PMID 20101189
FREQUENTLY ASKED
What is the difference between CJC-1295 + Ipamorelin (blend) and Tesamorelin?
This is the choice behind the CJC-1295 + Ipamorelin blend versus the Recomposition Stack (Ipamorelin + Tesamorelin): both pair Ipamorelin with a GHRH analogue. Tesamorelin is the full-length, clinically approved analogue with phase 3 data; CJC-1295 without DAC is a shorter, stabilised research fragment.
What is the regulatory status of CJC-1295 + Ipamorelin (blend) and Tesamorelin?
CJC-1295 + Ipamorelin (blend): A research blend of two investigational GH secretagogues; neither component is an approved medicine and the blend itself has not been studied. Tesamorelin: An approved medicine (US) for excess abdominal fat in HIV-associated lipodystrophy; research use elsewhere.
What safety signals have been reported?
CJC-1295 + Ipamorelin (blend): No human safety data for the blend; each component has only limited, short-term human exposure. Tesamorelin: Label-level trial data exist for its approved indication, including IGF-1 elevation and injection-site effects.
Which studies is this comparison based on?
For CJC-1295 + Ipamorelin (blend): “Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men” (PMID 2866496); “Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies” (PMID 9513600); “Ipamorelin, the first selective growth hormone secretagogue” (PMID 9849822). For Tesamorelin: “Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials” (PMID 20554713); “Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial” (PMID 25038357); “Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension” (PMID 20101189).
MORE COMPARISONS
All products supplied for research purposes only. Not for human consumption.
In stock · ships from South Africa
In stock now
Supplied for laboratory research only · not for human use